JOINN Laboratories (06127) saw its shares rise more than 7% in morning trading. At the time of writing, the stock was up 7.08%, trading at HKD 21.02 with a turnover of HKD 763.146 million.

Recently, during the company's Q1 2026 earnings briefing, JOINN Laboratories stated that the supply of cynomolgus monkeys within the industry remains tight. Price fluctuations for experimental monkeys primarily stem from shifts in supply and demand dynamics. Current demand has shown some recovery, leading to a relatively tight supply-demand balance. However, considering various uncertainties, future price trends still require ongoing observation. The company also indicated that, benefiting from the continued recovery in pharmaceutical R&D demand, rising monkey prices can gradually be passed through to newly signed orders, driving up product selling prices accordingly, creating a positive linkage between volume and price in line with market supply and demand changes.

According to data disclosed by JOINN Laboratories, the company secured new orders worth approximately RMB 910 million in Q1 2026, representing a year-on-year increase of 111.6%. As of the end of the first quarter, the company's order backlog stood at RMB 3.1 billion, up 40.9% year-on-year. During the earnings briefing, the company revealed that, so far, the order volume and pricing levels in the second quarter have generally maintained the trend seen in Q1. The company's capacity utilization remains at a high level but still possesses a degree of flexibility to be released, allowing it to flexibly accommodate subsequent new orders.